Characterization of probiotics isolated from dietary supplements and evaluation of metabiotic-antibiotic combinations as promising therapeutic options against antibiotic-resistant pathogens using time-kill assay.

Publisher: BioMed Central Country of Publication: England NLM ID: 101761232 Publication Model: Electronic Cited Medium: Internet ISSN: 2662-7671 (Electronic) Linking ISSN: 26627671 NLM ISO Abbreviation: BMC Complement Med Ther Subsets: MEDLINE

Original Publication: London : BioMed Central, [2020]-

Probiotics*/pharmacology ; Anti-Bacterial Agents*/pharmacology ; Dietary Supplements* ; Staphylococcus aureus*/drug effects ; Escherichia coli*/drug effects; Microbial Sensitivity Tests ; Humans ; Drug Resistance, Bacterial

Background: The global probiotics dietary supplements market size is continuously growing. To overcome probiotics' health concerns, metabiotics are recognized as a safer alternative. Aiming to deal with the escalating antimicrobial resistance, the current work demonstrates synergistic metabiotic-antibiotic combinations against antibiotic-resistant pathogens.
Methods: The probiotic properties of lactic acid bacteria (LAB) strains isolated from 3 commercial dietary supplements were characterized in vitro. The combinations of the cell-free supernatants (CFS) of selected probiotic strains and conventional antibiotics against Staphylococcus aureus and Escherichia coli clinical isolates were evaluated using the time-kill assay. To our knowledge, the current literature lacks sufficient time-kill assay studies revealing the kinetics of such metabiotic-antibiotic combinations against S. aureus and E. coli.
Results: Four LAB strains isolated from dietary supplements as well as two reference strains were included in this study. The isolated LAB strains were identified by MALDI-TOF mass spectrometry as follows: P2: Lactobacillus acidophilus, P3: Lactiplantibacillus plantarum, P4: Lacticaseibacillus rhamnosus, and P5: Pediococcus acidilactici. The identification matched with that annotated by the manufacturers, except for P3. The tested strains could resist the acidic environment at pH 3. Excluding P2, the examined strains showed less than 1 log reduction in survivors upon the addition of reconstituted skimmed milk to pepsin at pH 2 and displayed an acceptable tolerance to 0.3% ox-bile. All the strains tolerated pancreatin. The hydrophobicity and autoaggregation capacities ranged between 7-92% and 36-66%, respectively. P2 was excluded owing to its inferior probiotic potential. Although the remaining strains showed excellent growth at 0.2% phenol, their growth was reduced at higher concentrations. L. plantarum and P. acidilactici strains possessed bile salt hydrolysis activity. The time-kill assay revealed promising synergistic activities of the combinations of CFS of L. rhamnosus P4 with either ceftazidime or gentamicin against E. coli and with only ceftazidime against S. aureus, as well as CFS of P. acidilactici P5 and ceftazidime against S. aureus.
Conclusions: Strict identification and evaluation of the probiotic strains incorporated in dietary supplements is crucial to ensure their safety and efficacy. The CFS of probiotics could be utilized to formulate novel biotherapeutics targeting problematic pathogens. However, future in vivo studies are required to evaluate the appropriate treatment regimen.
(© 2024. The Author(s).)

Front Microbiol. 2017 May 19;8:908. (PMID: 28579981)
Biomed J. 2017 Oct;40(5):270-283. (PMID: 29179882)
J Med Food. 2014 Apr;17(4):487-95. (PMID: 24433075)
Metabol Open. 2022 May 21;14:100187. (PMID: 35651884)
Anaerobe. 2010 Dec;16(6):578-85. (PMID: 20951815)
Ann Clin Microbiol Antimicrob. 2011 Feb 27;10:9. (PMID: 21352573)
Appl Environ Microbiol. 1999 Jul;65(7):2901-6. (PMID: 10388681)
Int J Mol Sci. 2021 Oct 19;22(20):. (PMID: 34681948)
Appl Biochem Biotechnol. 2008 Dec;151(2-3):244-55. (PMID: 18592412)
Front Microbiol. 2023 May 05;14:1170725. (PMID: 37213505)
J Antibiot (Tokyo). 2011 Dec;64(12):795-8. (PMID: 22008700)
Lett Appl Microbiol. 2009 Oct;49(4):434-42. (PMID: 19725886)
Front Microbiol. 2013 Dec 24;4:396. (PMID: 24399996)
Front Microbiol. 2020 Feb 28;11:160. (PMID: 32184760)
Meat Sci. 2008 Nov;80(3):715-21. (PMID: 22063588)
BMC Microbiol. 2023 May 3;23(1):122. (PMID: 37138240)
Arch Microbiol. 2018 Mar;200(2):195-201. (PMID: 29075866)
J Appl Microbiol. 2003;94(6):981-7. (PMID: 12752805)
Antibiotics (Basel). 2022 Nov 05;11(11):. (PMID: 36358212)
Jundishapur J Microbiol. 2015 Apr 18;8(4):e16592. (PMID: 26034539)
Front Microbiol. 2018 Aug 06;9:1685. (PMID: 30127770)
Int J Food Microbiol. 2000 Jul 25;59(1-2):9-17. (PMID: 10946834)
J Appl Microbiol. 1998 May;84(5):759-68. (PMID: 9674129)
Biotechnol Adv. 2018 Dec;36(8):2060-2076. (PMID: 30266342)
Front Microbiol. 2022 Aug 01;13:918774. (PMID: 35979483)
BMC Microbiol. 2016 Oct 28;16(1):250. (PMID: 27793096)
Gut Pathog. 2017 Mar 6;9:12. (PMID: 28286570)
Foods. 2021 Jul 01;10(7):. (PMID: 34359389)
Front Microbiol. 2016 Dec 02;7:1940. (PMID: 27994577)
Food Microbiol. 2013 Apr;33(2):282-91. (PMID: 23200662)
Antimicrob Agents Chemother. 1999 Mar;43(3):525-9. (PMID: 10049262)
Res Microbiol. 2011 Apr;162(3):249-52. (PMID: 21288486)
Microbiol Immunol. 2009 Feb;53(2):59-65. (PMID: 19291088)
Front Microbiol. 2017 Jun 29;8:1205. (PMID: 28706513)
Probiotics Antimicrob Proteins. 2012 Sep;4(3):162-72. (PMID: 26782042)
Front Microbiol. 2023 Aug 17;14:1216674. (PMID: 37664108)
Antioxidants (Basel). 2023 Jan 17;12(2):. (PMID: 36829774)
BMC Microbiol. 2014 Dec 14;14:312. (PMID: 25495549)
Res Microbiol. 2006 Oct;157(8):792-801. (PMID: 16844349)
Probiotics Antimicrob Proteins. 2021 Feb;13(1):102-112. (PMID: 32415515)
Microorganisms. 2021 Feb 18;9(2):. (PMID: 33670726)
Braz J Microbiol. 2010 Oct;41(4):916-21. (PMID: 24031571)
GMS Hyg Infect Control. 2017 Sep 28;12:Doc15. (PMID: 28989854)
Drugs Exp Clin Res. 1985;11(5):335-8. (PMID: 2941261)
Food Microbiol. 2013 Oct;36(1):22-9. (PMID: 23764216)
Indian J Med Res. 2014 Sep;140(3):345-55. (PMID: 25366201)
Adv Mater. 2018 Dec;30(51):e1803925. (PMID: 30328144)
Front Microbiol. 2021 Jul 19;12:700138. (PMID: 34349743)
J Biol Chem. 2008 May 9;283(19):12769-76. (PMID: 18337244)
Probiotics Antimicrob Proteins. 2010 Oct;2(3):162-74. (PMID: 26781239)
Front Microbiol. 2016 Oct 21;7:1683. (PMID: 27818658)
J Microbiol Biotechnol. 2024 Mar 28;34(3):487-494. (PMID: 38247208)
Microorganisms. 2019 Jun 29;7(7):. (PMID: 31261869)
Front Microbiol. 2019 Apr 18;10:789. (PMID: 31057508)
Front Microbiol. 2018 Aug 22;9:1974. (PMID: 30186277)
Infect Drug Resist. 2023 May 23;16:3191-3211. (PMID: 37249957)
Curr Res Food Sci. 2021 May 12;4:320-325. (PMID: 34095855)
Crit Rev Microbiol. 2002;28(4):281-370. (PMID: 12546196)
Oral Dis. 2000 Jul;6(4):227-33. (PMID: 10918560)
J Antimicrob Chemother. 2007 Feb;59(2):246-53. (PMID: 17220162)
Medicina (Kaunas). 2023 May 15;59(5):. (PMID: 37241179)
Microb Cell Fact. 2020 Aug 20;19(1):168. (PMID: 32819443)
Int J Microbiol. 2019 Aug 25;2019:7179514. (PMID: 31534458)
Biomed Res Int. 2014;2014:927268. (PMID: 25105147)
J Food Prot. 2007 Mar;70(3):557-65. (PMID: 17388042)
Anaerobe. 2015 Jun;33:117-23. (PMID: 25771244)

Keywords: Acid tolerance; Autoaggregation; Bile salt hydrolysis; Cell surface hydrophobicity; Cell-free supernatants (CFS); MALDI-TOF mass spectrometry; Metabiotics; Phenol tolerance; Probiotic dietary supplements; Synergism; Time-kill assay

0 (Anti-Bacterial Agents)

Date Created: 20240814 Date Completed: 20240814 Latest Revision: 20240817

20240817

PMC11325838

10.1186/s12906-024-04582-3

39143578